Drugs

Jun 19, 2025, 15:30

Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma

Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:

“Nivo-AVD vs BV-AVD in older pts (60+) with Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access.”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivo-AVD vs BV-AVD

More Posts Featuring Hodgkin Lymphoma on OncoDaily.

Alex F. Herrera Anamarija M. Perry Andrew M. Evens Brad Kahl Brian T. Hess cancer Carla Casulo Graham Collins Hongli Li John P. Leonard Jonathan W. Friedberg Joo Y. Song Joseph M. Tuscano Joseph M. Unger Kelly Davison Michael LeBlanc Nancy L Bartlett OncoDaily Oncology Pallawi Torka Pankaj Kumar Ryan Jacobs Sairah Ahmed Sarah C. Rutherford Sharon M. Castellino Sonali M. Smith Susan K. Parsons

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care